Almirall SA
MAD:ALM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Almirall SA
MAD:ALM
|
ES |
Almirall SA
Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market.
The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.
Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market.
The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.
Strong Start: Almirall began 2025 with robust business performance and confirmed its full-year and midterm guidance.
Sales Growth: Net sales rose 15% year-on-year in Q1 2025, with European dermatology sales up 23.4%.
Ebglyss Momentum: Ebglyss sales increased 52% quarter-on-quarter, reaching EUR 19.4 million, and the product is now launched in 13 European countries.
Ilumetri Growth: Ilumetri sales grew 13% year-on-year to EUR 55 million, and the company reiterated its over EUR 300 million peak sales projection.
Profitability Up: EBITDA increased by 35% to EUR 70.9 million, with a gross margin of 66.9%.
Guidance Reiterated: Management reaffirmed 2025 guidance and midterm targets, projecting double-digit annual sales growth through 2030.
Pipeline Progress: R&D investment rose 34%, with major pipeline advances including new indications for Ebglyss and progress on the anti-IL-1RAP antibody.
No Major Divestments: Management does not plan significant divestments or business reshaping in the near term.
